BCL9 and melanoma: Recent studies have also shown that disrupting the interaction between β-catenin and BCL9 can also inhibit oncogenic WNT/β-catenin activity [85,86] and ST316, a novel peptide antagonist of β-catenin that inhibits the interaction with BCL9 and has recently entered the path of clinical trials (NCT05848739) and its activity is investigated in several cancer types including melanoma.